SNPHF (Santen Pharmaceutical Co) Total Liabilities: $800 Mil (As of Mar. 2026)


SNPHF Santen Pharmaceutical Co Ltd SNPHF
81 GF Score
Price $13.05
GF Value $10.29
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Santen Pharmaceutical Co Total Liabilities?

Santen Pharmaceutical Co SNPHF +4.40% 81 Total Liabilities is $800 Mil as of Mar. 2026. GuruFocus rates SNPHF with a GF Score™ of 81/100 and a GF Value™ of $10.29 (Modestly Overvalued). The stock has 6 warning signs investors should review.

Santen Pharmaceutical Co's Total Liabilities for the quarter that ended in Mar. 2026 was $800 Mil.

Santen Pharmaceutical Co's quarterly Total Liabilities declined from Sep. 2025 ($781.33 Mil) to Dec. 2025 ($761.47 Mil) but then increased from Dec. 2025 ($761.47 Mil) to Mar. 2026 ($800.44 Mil).

Santen Pharmaceutical Co's annual Total Liabilities declined from Mar. 2024 ($869.92 Mil) to Mar. 2025 ($832.54 Mil) and declined from Mar. 2025 ($832.54 Mil) to Mar. 2026 ($800.44 Mil).

Santen Pharmaceutical Co Total Liabilities Historical Data

* Premium members only.

The historical data trend for Santen Pharmaceutical Co's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Santen Pharmaceutical Co Total Liabilities Chart

Santen Pharmaceutical Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,038.41 956.74 869.92 832.54 800.44

Santen Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 832.54 885.28 781.33 761.47 800.44
SNPHF
81GF Score
Santen Pharmaceutical Co Ltd SNPHF
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Santen Pharmaceutical Co Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Santen Pharmaceutical Co's Total Liabilities for the fiscal year that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=553.734+(0+237.543
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+8.974+0.189)
=800

Total Liabilities=Total Assets (A: Mar. 2026 )-Total Equity (A: Mar. 2026 )
=2665.905-1865.465
=800

Santen Pharmaceutical Co's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=553.734+(0+237.543
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+8.974+0.189)
=800

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=2665.905-1865.465
=800

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $800 Mil mean?
Santen Pharmaceutical Co (SNPHF) has a Total Liabilities of $800 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Santen Pharmaceutical Co and its competitors.
Is Santen Pharmaceutical Co's Total Liabilities too high?
Santen Pharmaceutical Co's current Total Liabilities is $800 Mil. Overall, Santen Pharmaceutical Co has a GF Score™ of 81/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Santen Pharmaceutical Co's Total Liabilities compare to LLY and JNJ?
Santen Pharmaceutical Co's Total Liabilities of $800 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Drug Manufacturers company?
A good Total Liabilities depends on the Drug Manufacturers industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Santen Pharmaceutical Co and its competitors. Santen Pharmaceutical Co's current Total Liabilities is $800 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Santen Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Santen Pharmaceutical Co (SNPHF) is currently considered Modestly Overvalued. The stock's GF Value™ is $10.29, compared to a current price of $13.05 — trading 26.8% above its estimated fair value. The current Total Liabilities is $800 Mil. Santen Pharmaceutical Co's overall GF Score™ is 81/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Santen Pharmaceutical Co (SNPHF), the current Total Liabilities is $800 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Santen Pharmaceutical Co (SNPHF) Overvalued in 2026?

Based on GuruFocus' analysis, Santen Pharmaceutical Co stock appears to be overvalued. The current stock price of $13.05 is trading 26.8% above its estimated GF Value™ of $10.29. GuruFocus considers Santen Pharmaceutical Co to be Modestly Overvalued.

Key valuation signals for SNPHF:

  • Total Liabilities: $800 Mil
  • GF Value™: $10.29 vs. price of $13.05 (26.8% above fair value)
  • GF Score™: 81/100 with 6 warning signs

No single metric tells the full story. See the SNPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Santen Pharmaceutical Co Business Description

Other Exchanges SNPHY:USA4536:Japan
Address 4-20 Ofukacho, Grand Front Osaka Tower A, Kita-ku, Osaka Prefecture, Osaka, JPN, 530-8552
Santen Pharmaceutical Co Ltd is a drug manufacturing company that focuses on ophthalmic products. The company provides a wide range of prescription and over-the-counter eye care products, including treatments for glaucoma, dry eye, and allergies. It also develops surgical and diagnostic devices related to eye care.
81GF Score

Get the complete analysis for SNPHF

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.05
Price
$10.29
GF Value